Mosaic Immunoengineering Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Mosaic Immunoengineering Inc (PTSC) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
API endpoints for this dataset
Mosaic Immunoengineering Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Mosaic Immunoengineering Inc | - | - | - | Yes |
| Competitors combined (55) | ||||
| High-Confidence Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PTSC Stock Performance relative to its Competitors
PTSC Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 3 | Immunitybio inc | 282.9% | Outperformed |
| 4 | Revolution Medicines Inc | 282.9% | Outperformed |
| 5 | Vir Biotechnology Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Mosaic Immunoengineering Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Mosaic Immunoengineering Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Mosaic Immunoengineering Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Mosaic Immunoengineering Inc |
0.04 | - |
 Novartis Ag |
317,785.25 | 56,674.00 |
 Astrazeneca Plc |
291,203.66 | 58,739.00 |
 Amgen Inc |
250,468.48 | 38,095.00 |
 Gilead Sciences Inc |
208,779.39 | 30,988.00 |
 Gsk Plc |
207,208.61 | 43,093.89 |
| SUBTOTAL | 1,842,109.34 | 367,934.17 |
Sign in to see all competitors of Mosaic Immunoengineering Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Mosaic Immunoengineering Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Mosaic Immunoengineering Inc's Competitors Named by the Company
Competitive relationships identified from Mosaic Immunoengineering Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| AstraZeneca plc | Company report | 85% |
| Amgen, Inc. | Company report | 85% |
| Sanofi S.A. | Company report | 85% |
| Novartis AG | Company report | 85% |
| Pfizer Inc. | Company report | 85% |
| Genentech, Inc. | Company report | 85% |
| Merck & Co., Inc. | Company report | 85% |
| Bristol-Myers Squibb Company | Company report | 85% |
| BioNTech SE | Company report | 85% |
| Ascendis Pharma A/S | Company report | 85% |
| Sumitomo Dainippon Pharma Oncology, Inc. | Company report | 85% |
| Nektar Therapeutics | Company report | 85% |
Company report basis, confidence, active dates and source counts for Mosaic Immunoengineering Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Mosaic Immunoengineering Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
| Exelixis Inc | Reportable 100.00 % |
| Immunitybio inc | Reportable 100.00 % |
| Iovance Biotherapeutics inc | Single reportable segment 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Mosaic Immunoengineering Inc .
Mosaic Immunoengineering Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Mosaic Immunoengineering Inc | 0 | - | -98,192 |
| Novartis Ag | 317,785 | 752,973 | 185,566 |
| Astrazeneca Plc | 291,204 | 706,847 | 123,141 |
| Amgen Inc | 250,468 | 2,930,385 | 672,538 |
| Gilead Sciences Inc | 208,779 | 1,822,824 | -227,235 |
| Gsk Plc | 207,209 | 169,660,977 | 32,662,867 |
| PEERS TOTAL | 1,842,109 | 1,213,355 | 148,104 |
Sign in to see all peers for Mosaic Immunoengineering Inc .
Mosaic Immunoengineering Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 76.66 % |
| Pfizer Inc | United States 63.93 % |
| Exelixis Inc | United States 92.47 % |
| Krystal Biotech Inc | United States 74.86 % |
| Immunitybio inc | United States 98.99 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Mosaic Immunoengineering Inc .
Mosaic Immunoengineering Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 158 companies in Mosaic Immunoengineering Inc's industry classification, broader than the peer set above. Market cap in millions of $.Mosaic Immunoengineering Inc ranks #0 of 158 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,353, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 250,468 | 26.02 % |
| 2 | Gilead Sciences Inc | 207,444 | 21.55 % |
| 3 | Moderna Inc | 101,168 | 10.51 % |
| 4 | Argenx Se | 61,223 | 6.36 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Mesoblast Limited | 1,234 | 5.2% |
| 9 | Exelixis Inc | 1,234 | 5.2% |
| 10 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 0 | Mosaic Immunoengineering Inc | 0 | 0.00 % |
Market cap and industry share for the rest of Mosaic Immunoengineering Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2020-12-01.
Mosaic Immunoengineering Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Return on Invested Capital | -17.65 % | -40.34 % | -150.11 % | - | - | - | - | - |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Mosaic Immunoengineering Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,353 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Mosaic Immunoengineering Inc's dedicated Suppliers and Customers pages, not here.
Mosaic Immunoengineering Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (55.60 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Mosaic Immunoengineering Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Mosaic Immunoengineering Inc | 0.00 | 0.00 | - |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Gilead Sciences Inc | - | 1.52 | 1.47 |
| Gsk Plc | 0.16 | 0.82 | 0.87 |
Sign in to see all peers for Mosaic Immunoengineering Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Mosaic Immunoengineering Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Mosaic Immunoengineering Inc | Q2 2026 | - | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Gilead Sciences Inc | Q3 2026 | +6.8 % | -20.4 % |
| Gsk Plc | Q4 2025 | +7.5 % | +120.0 % |
| PEERS TOTAL | +8.9 % | +33.6 % |
Sign in to see all peers for Mosaic Immunoengineering Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Mosaic Immunoengineering Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Mosaic Immunoengineering Inc | Q2 2026 | - | - |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Gilead Sciences Inc | Q3 2026 | +0.1 % | +61.2 % |
| Gsk Plc | Q4 2025 | +7.2 % | -0.6 % |
Sign in to see all peers for Mosaic Immunoengineering Inc .
Mosaic Immunoengineering Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Mosaic Immunoengineering Inc | - | - | - |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Gilead Sciences Inc | - | - | - |
| Gsk Plc | 10.09% | 44.94% | 38.67% |
Sign in to see all peers for Mosaic Immunoengineering Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Mosaic Immunoengineering Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Mosaic Immunoengineering Inc | - | - |
| Novartis Ag | 22.73 | 5.61 |
| Astrazeneca Plc | 28.51 | 4.96 |
| Amgen Inc | 28.60 | 6.57 |
| Gilead Sciences Inc | - | 6.74 |
| Gsk Plc | 36.26 | 4.81 |
| PEERS AVERAGE | 41.02 | 5.01 |
Sign in to see all peers for Mosaic Immunoengineering Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.